Hims & Hers Shares Rebound Following Regulatory Setback

The stock of telehealth company Hims & Hers Health, Inc. experienced a period of significant volatility after receiving a formal warning from the U.S. Food and Drug Administration (FDA). Despite an initial sharp sell-off, the equity demonstrated notable resilience, staging a partial recovery that has left market participants divided on its near-term prospects.

Unexpected Recovery After Initial Plunge

Investor sentiment soured dramatically on September 16 when the FDA’s warning letter became public knowledge. The announcement triggered an immediate sell-off, sending shares down by as much as 8% during the trading session. The decline reflected mounting concerns over potential legal repercussions and lasting damage to the company’s brand reputation.

However, in a surprising reversal, the stock rallied on September 19. It climbed 3.5% at one point during the day before closing at $57.81, marking a gain of 2.9% for the session. This rebound suggests that certain investors are focusing on the company’s long-term growth narrative, choosing to look beyond the immediate regulatory challenges.

FDA Warning Targets Marketing Claims

The source of the recent turbulence was a direct and strongly worded communication from the regulatory agency dated September 9. The FDA accused the company of employing “false or misleading” advertising in the promotion of its compounded semaglutid products.

Central to the agency’s concerns was the alleged implication that Hims & Hers’ offerings are equivalent to approved drugs such as Ozempic and Wegovy. The FDA has demanded a formal response from the company within 15 business days, outlining concrete steps to correct these violations. Failure to provide an adequate response could result in severe enforcement actions, including product seizure or injunction.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Lingering Effects from Prior Partnership Dissolution

This is not the first time the company has faced scrutiny over its practices concerning weight-loss medications. The recent FDA action follows a significant prior development from June 2025, when pharmaceutical giant Novo Nordisk terminated its partnership with Hims & Hers.

Novo Nordisk cited specific apprehensions regarding the marketing and sale of combined GLP-1 therapies, alongside allegations of “deceptive” promotional strategies. The dissolution of that partnership, which was originally intended to make the weight-loss drug Wegovy available on the Hims & Hers platform, had previously precipitated a steep 30% decline in the company’s share price.

Insider Selling Adds to Investor Unease

Compounding the negative sentiment are recent transactions by company insiders. Corporate filings revealed that several executives, including Chief Executive Officer Andrew Dudum, disposed of substantial share blocks between July and September 2025.

Notably, CEO Dudum’s sale occurred on September 16, coinciding with the day of the stock’s sharp decline following the FDA news. The timing of these insider sales during a period of heightened regulatory uncertainty has likely done little to bolster investor confidence.

Whether the stock’s recent recovery can be sustained remains an open question. The company continues to navigate a complex regulatory landscape, and the long-term impact of these developments on its business model is yet to be fully understood by the market.